The lesions evaluated in this study that can become cancerous are known as intraductal papillary
mucinous neoplasms.
According to a new «proof of principle» study published in Aug. 27 issue of Cancer Prevention Research, Moffitt Cancer Center researchers hope to improve pancreatic cancer survival rates by identifying markers in the blood that can pinpoint patients with premalignant pancreatic lesions called intraductal papillary
mucinous neoplasms (IPMNs).
Not exact matches
Pancreatic Intraepithelial Neoplasia (PanIN) and
mucinous cystic
neoplasm (MCN) also are lesions that precede pancreatic cancer.
The test was less accurate for the less prevalent pancreatic cyst type called
mucinous cystic
neoplasm (MCN)-- catching only 30 percent of the cases.
Mucinous cystic
neoplasms (MCN) are a form of pancreatic tumor.